Table of Contents
ISRN Surgery
Volume 2011, Article ID 529876, 6 pages
http://dx.doi.org/10.5402/2011/529876
Clinical Study

Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results

1Surgical Department, Didimotichon General Hospital, Konstantinoupoleos 1, 68300 Didimotichon, Greece
2Surgical Department, Mesologgi General Hospital, Greece
3Department of Anesthesiology, Didimotichon General Hospital, Mesologgi, Greece
4Department of Anesthesiology, Mesologgi General Hospital, 68300 Didimotichon, Greece

Received 9 March 2011; Accepted 29 March 2011

Academic Editors: A. H. Al-Salem and D. M. D'Ugo

Copyright © 2011 A. A. K. Tentes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Aims. Intraperitoneal chemotherapy is a basic tool in the treatment of peritoneal malignancy. The purpose of the study is to investigate the effect of adjuvant perioperative intraperitoneal chemotherapy in the treatment of locally advanced colorectal cancer. Patients and Methods. Patients with T3 and T4 colorectal carcinomas that underwent R0 resection received either hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC g r o u p = 4 0 patients) or early postoperative intraperitoneal chemotherapy (EPIC g r o u p = 6 7 patients). The survival, the recurrences and the sites of recurrence were assessed. Results. The 3-year survival rate for HIPEC group was 100% and for EPIC group 69% ( 𝑃 = . 0 1 1 ). Nodal infiltration was found to be the single prognostic indicator of survival. The incidence of recurrence in EPIC group was higher than in HIPEC group ( 𝑃 = . 0 0 9 ). The independent indicators of recurrence were the use of HIPEC and the degree of differentiation ( 𝑃 < . 0 5 ). Conclusions. Intraperitoneal chemotherapy, particularly HIPEC, as an adjuvant in locally advanced colorectal carcinomas appears to improve survival and decrease the incidence of recurrence.